- Email: [email protected]
2J male mice” [Bone 82 (2016) 101–107]
BON-11193; No. of page: 1; 4C: Bone xxx (2016) xxx
Contents lists available at ScienceDirect
Bone journal homepage: www.elsevier.com/locate/bone
Corrigendum
Corrigendum to “SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice” [Bone 82 (2016) 101–107] Kathryn M. Thrailkill a,b,⁎, R.C. Bunn a,b, Jeffry S. Nyman c,d, Mallikarjuna R. Rettiganti e, Gael E. Cockrell e, Elizabeth C. Wahl e, Sasidhar Uppuganti c,d, Charles K. Lumpkin Jr e, John L. Fowlkes a,b a
University of Kentucky Barnstable Brown Diabetes and Obesity Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, USA c VA Tennessee Valley Health Care System, Department of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, USA d VA Tennessee Valley Health Care System, Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA e Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute, Little Rock, AR 72202, USA b
The authors regret Fig. 2D is incorrect. Bars were erroneously graphed using data for standard deviation (SD) rather than the mean and were presented as SD+-SD rather than as mean + -SD. This was an error in graphing only and not in accuracy or validity of the results. The correct figure appears below.
p<0.0001
50
15 10
0 STZ+VEHICLE CONT+CANA CONT+VEHICLE
STZ+CANA 800
RatLaps
C
700
p=0.0046
D
STZ+VEHICLE CONT+CANA CONT+VEHICLE
FGF23 p=0.046
600
p<0.0001
500
40 ng/ml
B
20
5
STZ+CANA
60
p<0.0001
ng/ml
A
P1NP 25
p=0.0002
30
pg/ml
pg/ml
PTH 1000 900 800 700 600 500 400 300 200 100 0
400 300
20
200
10
100
0 STZ+CANA
STZ+VEHICLE CONT+CANA CONT+VEHICLE
0 STZ+CANA
STZ+VEHICLE CONT+CANA CONT+VEHICLE
Fig. 2. Bone biomarker analyses.
The authors would like to apologise for any inconvenience caused. DOI of original article: http://dx.doi.org/10.1016/j.bone.2015.07.025. ⁎ Corresponding author at: University of Kentucky Barnstable Brown Diabetes and Obesity Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA. E-mail address: [email protected] (K.M. Thrailkill).
http://dx.doi.org/10.1016/j.bone.2016.11.021 8756-3282/
Please cite this article as: K.M. Thrailkill, et al., , Bone (2016), http://dx.doi.org/10.1016/j.bone.2016.11.021
Contents lists available at ScienceDirect
Bone journal homepage: www.elsevier.com/locate/bone
Corrigendum
Corrigendum to “SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice” [Bone 82 (2016) 101–107] Kathryn M. Thrailkill a,b,⁎, R.C. Bunn a,b, Jeffry S. Nyman c,d, Mallikarjuna R. Rettiganti e, Gael E. Cockrell e, Elizabeth C. Wahl e, Sasidhar Uppuganti c,d, Charles K. Lumpkin Jr e, John L. Fowlkes a,b a
University of Kentucky Barnstable Brown Diabetes and Obesity Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, USA c VA Tennessee Valley Health Care System, Department of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, USA d VA Tennessee Valley Health Care System, Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA e Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute, Little Rock, AR 72202, USA b
The authors regret Fig. 2D is incorrect. Bars were erroneously graphed using data for standard deviation (SD) rather than the mean and were presented as SD+-SD rather than as mean + -SD. This was an error in graphing only and not in accuracy or validity of the results. The correct figure appears below.
p<0.0001
50
15 10
0 STZ+VEHICLE CONT+CANA CONT+VEHICLE
STZ+CANA 800
RatLaps
C
700
p=0.0046
D
STZ+VEHICLE CONT+CANA CONT+VEHICLE
FGF23 p=0.046
600
p<0.0001
500
40 ng/ml
B
20
5
STZ+CANA
60
p<0.0001
ng/ml
A
P1NP 25
p=0.0002
30
pg/ml
pg/ml
PTH 1000 900 800 700 600 500 400 300 200 100 0
400 300
20
200
10
100
0 STZ+CANA
STZ+VEHICLE CONT+CANA CONT+VEHICLE
0 STZ+CANA
STZ+VEHICLE CONT+CANA CONT+VEHICLE
Fig. 2. Bone biomarker analyses.
The authors would like to apologise for any inconvenience caused. DOI of original article: http://dx.doi.org/10.1016/j.bone.2015.07.025. ⁎ Corresponding author at: University of Kentucky Barnstable Brown Diabetes and Obesity Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA. E-mail address: [email protected] (K.M. Thrailkill).
http://dx.doi.org/10.1016/j.bone.2016.11.021 8756-3282/
Please cite this article as: K.M. Thrailkill, et al., , Bone (2016), http://dx.doi.org/10.1016/j.bone.2016.11.021